UNSPSC 51272206: Esketamine hydrochloride

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L8P1H35P2Z. European Medicines Agency schedules Esketamine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25811. Esketamine hydrochloride generally arises in the molecular formula C13H16CLNO.CLH. The term 'esketamine hydrochloride' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule esketamine hydrochloride under HS 29223900 and SITC 51463.

As of Q4 2014, ESKETAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN[C@@]1(CCCCC1=O)C2CCCCC2CL.CL.

UNSPSC 51272206 Esketamine hydrochloride is a Commodity code that nominally covers a specific pharmaceutical ingredient, but recent state and local procurement activity under this code shows little direct relevance to esketamine itself. The three recent opportunities posted between January and June 2026 involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy benefit programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations explicitly name esketamine or reference its procurement. The issuing bodies span county health departments, state health agencies, and multi-state cooperative purchasing alliances; this suggests the code may be applied broadly to pharmaceutical procurement categories rather than to esketamine specifically.

Geographic activity centers on Florida, Texas, and Minnesota, with interstate reach through MMCAP's multi-state cooperative structure. The most concrete opportunity is Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, closing July 26, 2023 (note: the posted date of June 30, 2026 conflicts with the stated due date of 2023, creating a data inconsistency). Texas HHS issued an exploratory RFI on direct-to-manufacturer prescription programs with a response deadline of April 3, 2026, designed to inform future formal procurement strategy rather than to award a contract immediately. Minnesota's MMCAP RFP for generic pharmaceuticals and OTC products, posted January 20, 2026 with proposals due March 26, 2026, awards multiple contracts through three authorized wholesalers with effectiveness from July 1, 2026. The disconnect between the code's nominal scope and the actual work being solicited suggests either a categorization mismatch in state and local procurement systems or a broader pharmaceutical-supply umbrella use of this commodity code.